ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 92 filers reported holding ORIC PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 6.67 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,971,862 | +106.4% | 1,978,820 | +164.7% | 1.31% | -12.4% |
| Q2 2023 | $5,800,988 | +36.1% | 747,550 | 0.0% | 1.49% | -60.1% |
| Q1 2023 | $4,261,035 | -3.2% | 747,550 | 0.0% | 3.74% | -9.2% |
| Q4 2022 | $4,403,070 | +84.1% | 747,550 | 0.0% | 4.12% | +85.5% |
| Q3 2022 | $2,392,000 | -28.6% | 747,550 | 0.0% | 2.22% | -22.0% |
| Q2 2022 | $3,349,000 | -16.1% | 747,550 | 0.0% | 2.85% | +22.8% |
| Q1 2022 | $3,992,000 | -63.7% | 747,550 | 0.0% | 2.32% | -62.9% |
| Q4 2021 | $10,989,000 | -32.4% | 747,550 | -3.8% | 6.25% | -20.9% |
| Q3 2021 | $16,251,000 | -7.8% | 777,193 | -22.0% | 7.90% | +38.0% |
| Q2 2021 | $17,632,000 | -27.8% | 996,734 | 0.0% | 5.72% | -30.0% |
| Q1 2021 | $24,420,000 | -48.5% | 996,734 | -28.8% | 8.17% | -18.6% |
| Q4 2020 | $47,405,000 | – | 1,400,435 | – | 10.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $161,403,000 | 14.64% |
| Invus Financial Advisors, LLC | 1,007,575 | $34,106,000 | 14.26% |
| Euclidean Capital LLC | 1,400,435 | $47,405,000 | 10.04% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $20,387,000 | 8.63% |
| EcoR1 Capital, LLC | 3,092,218 | $104,672,000 | 5.63% |
| Ally Bridge Group (NY) LLC | 413,061 | $13,982,000 | 2.40% |
| Asymmetry Capital Management, L.P. | 67,210 | $2,275,000 | 1.04% |
| Orbimed Advisors | 2,921,967 | $98,909,000 | 0.86% |
| Casdin Capital, LLC | 601,515 | $20,361,000 | 0.60% |
| EMERALD ADVISERS, LLC | 522,302 | $17,680,000 | 0.59% |